Intellia Therapeutics granted China patent for CRISPR technology

20-06-2017

Intellia Therapeutics granted China patent for CRISPR technology

Ralwel / iStockphoto.com

Genome editing company Intellia Therapeutics has been granted a patent from China’s State Intellectual Property Office (SIPO) covering the CRISPR/Cas9 technology.


Intellia Therapeutics, China, CRISPR, patent, DNA, SIPO

LSIPR